article Open AccessTop 1% cited
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Clinical Cancer Research · 2007 · Vol. 13(15) · pp. 4429–4434
Rebecca Dent✉(Sunnybrook Health Science Centre)Maureen Trudeau(University of Toronto)Kathleen I. Pritchard(Sunnybrook Health Science Centre)Wedad Hanna(University of Toronto)Harriet K. Kahn(Sunnybrook Health Science Centre)Carol Sawka(Sunnybrook Health Science Centre)L. Lickley(Sunnybrook Health Science Centre)Ellen Rawlinson(Women's College Hospital)Ping Sun(University of Toronto)Steven A. Narod(University of Toronto)
Abstract
Triple-negative breast cancers have a more aggressive clinical course than other forms of breast cancer, but the adverse effect is transient.
Breast Cancer Treatment StudiesCancer Genomics and DiagnosticsAdvanced Breast Cancer TherapiesBreast cancerMedicineTriple-negative breast cancerHazard ratioInternal medicineOncologyConfidence intervalCancerCohortProportional hazards model
MeSH terms
Breast NeoplasmsFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorCohort StudiesDatabases, FactualCarcinoma, Ductal, BreastRisk AssessmentReceptor, ErbB-2Erb-b2 Receptor Tyrosine Kinases
Citations
5,037
FWCI
36.73
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
Cited by
Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes
The Journal of Pathology · 2013 · 485 citations
The role of p53 in cancer drug resistance and targeted chemotherapy
Oncotarget · 2016 · 570 citations
Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer
Oncotarget · 2014 · 364 citations
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge
Cells · 2019 · 835 citations
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Journal of Clinical Investigation · 2011 · 5,405 citations
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
Breast Cancer Research and Treatment · 2007 · 319 citations
Pattern of metastatic spread in triple-negative breast cancer
Breast Cancer Research and Treatment · 2008 · 555 citations
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Breast Cancer Research and Treatment · 2017 · 750 citations
References
Expression of luminal and basal cytokeratins in human breast carcinoma
The Journal of Pathology · 2004 · 597 citations
High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
International Journal of Cancer · 2005 · 611 citations
Molecular portraits of human breast tumours
Nature · 2000 · 16,173 citations
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
Clinical Cancer Research · 2004 · 2,652 citations
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Proceedings of the National Academy of Sciences · 2001 · 10,888 citations
Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome
American Journal Of Pathology · 2002 · 563 citations
Repeated observation of breast tumor subtypes in independent gene expression data sets
Proceedings of the National Academy of Sciences · 2003 · 5,398 citations
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
JAMA · 2006 · 3,808 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.